205 related articles for article (PubMed ID: 27488872)
1. Inhibition of SKP2 Sensitizes Bromocriptine-Induced Apoptosis in Human Prolactinoma Cells.
Huang J; Zhang F; Jiang L; Hu G; Sun W; Zhang C; Ding X
Cancer Res Treat; 2017 Apr; 49(2):358-373. PubMed ID: 27488872
[TBL] [Abstract][Full Text] [Related]
2. Tumor suppressor miR-145-5p sensitizes prolactinoma to bromocriptine by downregulating TPT1.
Jian M; Du Q; Zhu D; Mao Z; Wang X; Feng Y; Xiao Z; Wang H; Zhu Y
J Endocrinol Invest; 2019 Jun; 42(6):639-652. PubMed ID: 30370446
[TBL] [Abstract][Full Text] [Related]
3. Curcumin Sensitizes Prolactinoma Cells to Bromocriptine by Activating the ERK/EGR1 and Inhibiting the AKT/GSK-3β Signaling Pathway In Vitro and In Vivo.
Tang C; Zhu J; Yuan F; Yang J; Cai X; Ma C
Mol Neurobiol; 2021 Dec; 58(12):6170-6185. PubMed ID: 34463926
[TBL] [Abstract][Full Text] [Related]
4. The role of MAPK11/12/13/14 (p38 MAPK) protein in dopamine agonist-resistant prolactinomas.
Wang S; Wang A; Zhang Y; Zhu K; Wang X; Chen Y; Wu J
BMC Endocr Disord; 2021 Nov; 21(1):235. PubMed ID: 34814904
[TBL] [Abstract][Full Text] [Related]
5. The effect of octreotide and bromocriptine on expression of a pro-apoptotic Bax protein in rat prolactinoma.
Gruszka A; Kunert-Radek J; Pawlikowski M
Folia Histochem Cytobiol; 2004; 42(1):35-9. PubMed ID: 15046398
[TBL] [Abstract][Full Text] [Related]
6. PGAM5-CypD pathway is involved in bromocriptine-induced RIP3/MLKL-dependent necroptosis of prolactinoma cells.
Zhang SL; Tang HB; Hu JT; Zang ZL; Ding X; Li S; Yang H
Biomed Pharmacother; 2019 Mar; 111():638-648. PubMed ID: 30611988
[TBL] [Abstract][Full Text] [Related]
7. Dopamine agonist resistance-related endocan promotes angiogenesis and cells viability of prolactinomas.
Cai L; Leng ZG; Guo YH; Lin SJ; Wu ZR; Su ZP; Lu JL; Wei LF; Zhuge QC; Jin K; Wu ZB
Endocrine; 2016 Jun; 52(3):641-51. PubMed ID: 26662185
[TBL] [Abstract][Full Text] [Related]
8. Dopamine receptor D2S gene transfer improves the sensitivity of GH3 rat pituitary adenoma cells to bromocriptine.
Li Q; Su Z; Liu J; Cai L; Lu J; Lin S; Xiong Z; Li W; Zheng W; Wu J; Zhuge Q; Wu Z
Mol Cell Endocrinol; 2014 Jan; 382(1):377-384. PubMed ID: 24184771
[TBL] [Abstract][Full Text] [Related]
9. Alteration of G alpha subunits mRNA levels in bromocriptine resistant prolactinomas.
Caccavelli L; Morange-Ramos I; Kordon C; Jaquet P; Enjalbert A
J Neuroendocrinol; 1996 Oct; 8(10):737-46. PubMed ID: 8910802
[TBL] [Abstract][Full Text] [Related]
10. Bromocriptine Induces Autophagy-Dependent Cell Death in Pituitary Adenomas.
Geng X; Ma L; Li Z; Li Z; Li J; Li M; Wang Q; Chen Z; Sun Q
World Neurosurg; 2017 Apr; 100():407-416. PubMed ID: 28137551
[TBL] [Abstract][Full Text] [Related]
11. Curcumin (diferuloylmethane) inhibits cell proliferation, induces apoptosis, and decreases hormone levels and secretion in pituitary tumor cells.
Miller M; Chen S; Woodliff J; Kansra S
Endocrinology; 2008 Aug; 149(8):4158-67. PubMed ID: 18450960
[TBL] [Abstract][Full Text] [Related]
12. Involvement of p38 mitogen-activated protein kinase activation in bromocriptine-induced apoptosis in rat pituitary GH3 cells.
Kanasaki H; Fukunaga K; Takahashi K; Miyazaki K; Miyamoto E
Biol Reprod; 2000 Jun; 62(6):1486-94. PubMed ID: 10819748
[TBL] [Abstract][Full Text] [Related]
13. Estrogen receptor α/prolactin receptor bilateral crosstalk promotes bromocriptine resistance in prolactinomas.
Xiao Z; Yang X; Zhang K; Liu Z; Shao Z; Song C; Wang X; Li Z
Int J Med Sci; 2020; 17(18):3174-3189. PubMed ID: 33173437
[TBL] [Abstract][Full Text] [Related]
14. Decreased expression of the two D2 dopamine receptor isoforms in bromocriptine-resistant prolactinomas.
Caccavelli L; Feron F; Morange I; Rouer E; Benarous R; Dewailly D; Jaquet P; Kordon C; Enjalbert A
Neuroendocrinology; 1994 Sep; 60(3):314-22. PubMed ID: 7969790
[TBL] [Abstract][Full Text] [Related]
15. The expression of the F-box protein Skp2 is negatively associated with p27 expression in human pituitary tumors.
Musat M; Korbonits M; Pyle M; Gueorguiev M; Kola B; Morris DG; Powell M; Dumitrache C; Poiana C; Grossman AB
Pituitary; 2002; 5(4):235-42. PubMed ID: 14558671
[TBL] [Abstract][Full Text] [Related]
16. Bromocriptine and cabergoline induce cell death in prolactinoma cells via the ERK/EGR1 and AKT/mTOR pathway respectively.
Tang C; Sun R; Wen G; Zhong C; Yang J; Zhu J; Cong Z; Luo X; Ma C
Cell Death Dis; 2019 Apr; 10(5):335. PubMed ID: 31000722
[TBL] [Abstract][Full Text] [Related]
17. Resistance to dopamine agonists in prolactinoma is correlated with reduction of dopamine D2 receptor long isoform mRNA levels.
Shimazu S; Shimatsu A; Yamada S; Inoshita N; Nagamura Y; Usui T; Tsukada T
Eur J Endocrinol; 2012 Mar; 166(3):383-90. PubMed ID: 22127489
[TBL] [Abstract][Full Text] [Related]
18. Hyperprolactinemia and prolactinoma.
Romijn JA
Handb Clin Neurol; 2014; 124():185-95. PubMed ID: 25248588
[TBL] [Abstract][Full Text] [Related]
19. The role of TGF-β/Smad signaling in dopamine agonist-resistant prolactinomas.
Li Z; Liu Q; Li C; Zong X; Bai J; Wu Y; Lan X; Yu G; Zhang Y
Mol Cell Endocrinol; 2015 Feb; 402():64-71. PubMed ID: 25578603
[TBL] [Abstract][Full Text] [Related]
20. Caveolin-1 sensitizes rat pituitary adenoma GH3 cells to bromocriptine induced apoptosis.
Jiang YN; Li YH; Ke MW; Tseng TY; Tang YB; Huang MC; Cheng WT; Ju YT
Cancer Cell Int; 2007 Mar; 7():1. PubMed ID: 17331262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
